Wiredja Online News Logo

WiredJa Online News

Wiredja Online News Logo

WiredJa Online News

CUBA | Cuban vaccine Soberana Plus protects against Covid-19 reinfection

  • Written by Prensa Latina
  • Published in Health
Featured CUBA |  Cuban vaccine Soberana Plus protects against Covid-19 reinfection
Havana, Apr 12 (Prensa Latina) A single dose of Cuba's vaccine candidate Soberana Plus can protect people against Covid-19 reinfection and improve their immune response to variants of the SARS-CoV-2 coronavirus, health authorities announced on Monday.

At a press conference on Cuban television, Dr. Rolando Ochoa, a researcher with the Finlay Vaccines Institute (IFV) and project leader, explained that Soberana Plus has been designed for convalescents and as reinforcement for those who have been vaccinated with Soberana 02 in its phase III of clinical trials.

Soberana Plus was recently approved for phase II of clinical trials, and will be administered to 450 volunteers who suffered from Covid-19 with a mild, moderate or asymptomatic clinical history.

'It will be a multicenter, adaptive study in parallel random groups, a double-blind and control study with a placebo,' Ochoa noted.

The study involves patients aged 19-80 who were discharged from hospitals at least two months before receiving a single dose of Soberana Plus.

The Soberana vaccines are produced by the Finlay Institute in partnership with the Centre for Molecular Immunology and the National Biopreparations Centre.

The name Soberana means “sovereign”, reflecting their economic and political importance for the island – without this domestic production, Cuba would struggle to access foreign vaccines either because of their cost in international markets or because of the longstanding US embargo.

These vaccines work by inserting genetic information into superior mammalian cells. Soberana Plus is the first vaccine for convalescent COVID-19 patients to reach the clinical trial stage.

Last modified onMonday, 12 April 2021 19:52
  • Countries: Cuba